Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid-and long-term prediction of hepatocellular carcinoma among cirrhotic patients

BACKGROUND The combination of alpha-fetoprotein(AFP)and squamous cell carcinoma antigen immunocomplex(SCCA-IgM)have been proposed for its use in the screening of hepatocellular carcinoma(HCC).Current screening programs for all cirrhotic patients are controversial and a personalized screening is an unmet need in the precision medicine era.AIM To determine the role of the combination of SCCA-IgM and AFP in predicting mid-and long-term appearance of HCC.METHODS Two-hundred and three cirrhotic patients(Child A 74.9%,B 21.2%,C 3.9%)were followed-up prospectively every six months to screen HCC by ultrasound and AFP according to European Association for the Study of the Liver guidelines.The estimation cohort was recruited in Italy(30.5%;62/203)and validation cohort from Spain(69.5%;141/203).Patients underwent to evaluate SCCA-IgM by enzyme-linked immunosorbent assay(Hepa-IC,Xeptagen,Italy)and AFP levels at baseline.Patients were followed-up for 60 mo,being censored at the time of the appearance of HCC.RESULTS There were 10.8%and 23.1%of HCC development at two-and five-years followup.Patients with HCC showed higher levels of SCCA-IgM than those without it(425.72±568.33 AU/mL vs 195.93±188.40 AU/mL,P=0.009)during the fiveyear follow-up.In multivariate analysis,after adjusting by age,sex,aspartate transaminase and Child-Pugh,the following factors were independently associated with HCC:SCCA-IgM[Hazard ratio(HR)=1.001,95%CI:1.000-1.002;P=0.003],AFP(HR=1.028,95%CI:1.009-1.046;P=0.003)and creatinine(HR=1.56495%CI:1.151-2.124;P=0.004).The log-rank test of the combination resulted in 7.488(P=0.024)in estimation cohort and 11.061(P=0.004)in the validation cohort,and a 100%of correctly classified rate identifying a low-risk group in both cohorts in the two-year follow-up.CONCLUSION We have constructed a predictive model based on the combination of SCCA-IgM and AFP that provides a new HCC screening method,which could be followed by tailored HCC surveillance for individual patients,especially for those cirrhotic patients belonging to the subgroup identified as low-risk of HCC development.

Clinical applications of squamous cell carcinoma antigenimmunoglobulins M to monitor chronic hepatitis C

Hepatitis C virus(HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma(HCC), one of the most common fatal cancers worldwide- fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M(SCCA-Ig M), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-Ig M may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology.

High expression of squamous cell carcinoma antigen in poorly differentiated adenocarcinoma of the stomach: A case report

BACKGROUND Squamous cell carcinoma antigen(SCCA)is regarded as a specific indicator of epithelial malignancies and is widely used in the diagnosis of squamous cell carcinoma(SCC).However,the expression of SCCA in gastric adenocarcinoma has not been studied in detail.CASE SUMMARY A 52-year-old man was admitted to our hospital for a 2.5 cm x 2.5 cm ulcer at the antrum-body junction with dull pain and fullness in the upper abdomen for 2 mo.His pre-surgery serological testing results showed 0.51 ng/mL SCCA(reference interval,<1.5 ng/mL)and 9.9 ng/mL carcinoembryonic antigen(reference range,<4.7 ng/mL).He underwent radical distal gastrectomy and Roux-en Y anastomosis and was diagnosed with poorly differentiated mucinous adenocarcinoma(Lauren classification:Diffuse)by pathological examination of the resected lesion.Immunohistochemistry showed that SCCA was highly expressed in the cytoplasm of cancer cells.After surgery,the patient received an S-1 adjuvant chemotherapy regimen for six cycles containing tegafur,gimeracil,and oteracil potassium.He showed no sign of recurrence or metastasis within 24-mo follow-up.CONCLUSION This is a frontal report of SCCA overexpression in poorly differentiated adenocarcinoma of the stomach.

Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers

Objective: To determine if an amniotic fluid (AF)-specific marker is present and if its concentration changes with the presence of labor. Study Design: Twenty-six healthy women who gave birth to healthy newborns at term during the period from July 2009 to January 2010 were included in the study. Six candidate markers were assessed by commercially available ELISA kits: interleukin (IL)-6, squamous cell carcinoma (SCC) antigen, insulin-like growth factor (IGFBP)-1, osteopontin (OPN), CA125, and sialyl Tn (STN). Results: The AF/maternal serum (MS) measurement based on IL-6 or SCC has proved to be superior to IGFBP-1, CA125, OPN and STN. Women with spontaneous labor at term had significantly higher IL-6 and IGFBP-1 concentrations in AF compared with those without labor. No significant differences were observed in the AF concentrations of SCC, OPN, CA125 and STN between women with labor and those not in labor. Conclusion: Our observation of IL-6 and SCC in AF may open a new area of research to assess their usefulness as biological markers of obstetrical disorders.

Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma

Background: Several previous researchers have investigated the prognostic value of serum tumor markers, especially carcinoembryonic antigen (CEA). Only a limited number of studies reported the usefulness of serum tumor markers for lung squamous cell carcinoma (SQ). We aimed to examine the significance of serum tumor markers for lung SQ. Methods: Eighty-five lung SQ patients who underwent surgery and followed more than 5-year were included. The ratios of 5-year survivors to all patients in groups with several clinicopathologic factors, including tumor markers, were compared. We also compared the clinicopathologic factors between central type and peripheral type SQ. Results: The majority of patients were male gender and current/ former smokers. Age, pN status, cytokeratin-19 fragment (CYFRA 21-1), squamous cell carcinoma antigen (SCC), and comorbid interstitial pneumonia (IP) were associated with the ratio of 5-year survivors significantly. When patients were compared based on tumor location, high p-stage and CYFRA 21-1 were related to central type SQ. Conclusion: Both SCC and CYFRA 21-1 appeared to be useful prognostic markers for patients with lung SQ. Furthermore, CYFRA 21-1 was related to central type SQ.

Partial Trisomy 1q21-qter and Partial Monosomy 7q21-qter Due to a Derivative Chromosome 7 in Myelodysplastic Syndrome Associated with Squamous Cell Carcinoma: Case Report

Background: Myelodysplastic syndromes (MDS) are subtypes of hematological disorders which are known to have partial bone marrow dysplasia, peripheral cytopenia, and later on an increased risk to develop acute myeloid leukemia. Chromosomal aberrations are detected in ~50% of cases of de novo MDS cases and the most common chromosomal abnormalities of this entity include complete or partial monosomy of chromosomes 5 and 7, partial deletion of 20q and 12p, trisomy 8, and 11q23 aberrations. A few primary and/or secondary MDS cases combined with other cancer have been reported. Case Presentation: We report here an adult MDS associated with squamous cell carcinoma (SCC). G-banding and array-proven multicolor banding (aMCB) revealed an unbalanced translocation der(7)t(1;7)(q21;q21), which led to 1q partial trisomy and 7q partial monosomy. Immunophenotype of this case was consistent with refractory anemia with excess of blasts (RAEB-2) according to World Health Organization (WHO) classification. Conclusions: As far as we know, this is the first adult MDS case associated with SCC and an unbalanced translocation t(1;7). Our patient received first cycle of azacitidine treatment and he showed bilateral pleural effusion as a secondary event. This toxicity is not limited to the first cycle as in previous MDS cases;our case is the first one to shown this toxicity as a secondary event of azacitidine treatment. As less than 10 cytogenetcially comparable cases without SCC were reported before in male MDS, we carefully conclude that this cytogenetic aberration may be a hint on a new gender associated MDS subgroup.

Tumour Associated Tissue Eosinophilia as a Prognostic Indicator in Squamous Cell Carcinoma of Upper Aerodigestive Tract

Immune response is known to develop against malignant tumours. Malignant tumours express newer antigen on their cell surface membrane which elicit immunological reaction in and around tumoural tissue. In early part of immune reaction neutrophil, eosinophil migrates followed by monocyte-macrophage cell. Tumor associated tissue eosinophilia (TATE) is believed to play a significant role in the biological behavior of the carcinoma. Eosinophil infiltrate in association with the head and neck squamous cell carcinoma (SCC) have been reviewed from time-to-time. The significance of such an association has been variably thought to be either a potential diagnostic tool for stromal invasion or as a prognostic indicator. The aim of this study was to investigate and evaluate the possible role of the tumour associated tissue eosinophilia (TATE) as a predictive indicator for the grading and establishing prognosis of the upper aerodigestive tract squamous cell carcinoma (SCC).

宫颈癌患者血清SCC-Ag、NLR水平与临床病理特征及预后关系

目的:探讨宫颈癌患者血清鳞状细胞癌抗原(SCC-Ag)、中性粒细胞与淋巴细胞比值(NLR)与临床病理特征及预后关系。方法:纳入2018年1月-2023年1月本院收治的108例宫颈癌患者为宫颈癌组,宫颈上皮内瘤病变(CIN)患者108例为CIN组,健康体检健康女性108例为对照组。比较3组血清SCC-Ag、NLR水平,分析宫颈癌组血清SCC-Ag、NLR水平与临床病理特征及与预后关系。结果:血清SCC-Ag、NLR水平,宫颈癌组(7.35±1.76、4.65±1.06)、CIN组(2.06±0.53、3.41±0.89)、对照组(0.54±0.12、1.53±0.34)依次降低(P<0.05)。宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级、肌层浸润深度和盆腔淋巴结转移有关(P<0.05)。Kaplan-Meier显示,SCC-Ag、NLR高表达组总生存率、无病生存率均低于SCC-Ag、NLR低表达组,SCC-Ag高表达+NLR高表达组总生存率、无病生存率最低(均P<0.05)。结论:宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级和肌层浸润深度等有关,且SCC-Ag、NLR水平越高患者预后越差。

肺癌患者血清CA724、CA153、SCC水平与病理特征及术后复发转移的关系

目的探讨肺癌(LC)患者血清糖类抗原724(CA724)、糖类抗原153(CA153)、鳞癌抗原(SCC)水平与病理特征及术后复发转移的关系。方法选取2019年6月至2020年12月在周口市中心医院接受手术治疗的102例LC患者,根据其2 a后是否存在复发转移分为复发转移组和未复发转移组,比较两组术前血清CA724、CA153和SCC水平及病理特征,分析影响术后复发转移的因素。结果随访后,102例患者中有65例发生复发转移,发生率为63.73%;复发转移组CA724、CA153和SCC水平均高于未复发转移组(P<0.05);腺癌组CA724水平高于小细胞肺癌组和鳞癌组(P<0.05),3组CA153水平差异无统计学意义(P>0.05);鳞癌组SCC水平高于小细胞肺癌组和腺癌组(P<0.05)。Ⅱ期和Ⅲ期CA724、CA153和SCC水平高于Ⅰ期(P<0.05)。复发转移组和未复发转移组TNM分期和分化程度差异有统计学意义(P<0.05)。Cox单因素回归分析结果显示,TNM分期、高水平CA724、CA153、SCC和分化程度是LC患者术后复发转移的影响因素(P<0.05);多因素回归分析结果显示,TNM分期为Ⅲ期和高水平的CA724、CA153和SCC均为影响LC患者术后复发转移的独立危险因素(P<0.05)。结论LC患者血清CA724、CA153、SCC表达水平与LC病理特征和术后复发转移关系密切,临床可通过检测血清CA724、CA153、SCC水平来评估术后复发转移情况。

术后血清MMP-2、SCCA1表达水平对鼻腔鼻窦内翻性乳头状瘤术后复发的预测价值

目的探讨术后血清基质金属蛋白酶-2(MMP-2)、鳞状细胞癌抗原1(SCCA1)表达水平对鼻腔鼻窦内翻性乳头状瘤(SNIP)患者术后复发的预测价值。方法回顾性分析手术治疗的SNIP患者65例,根据术后2年内复发情况,将其分为复发组(n=12)和未复发组(n=53)。Elisa法检测手术前后血清MMP-2、SCCA1表达水平。收录临床资料,包括性别、年龄、饮酒史、吸烟史、肿瘤部位、手术方式、术后有无应用5-氟尿嘧啶(5-Fluorouracil,5-FU)、Krouse分期及有无糖尿病、高血压;Logistic回归分析影响SNIP患者术后复发的危险因素;ROC曲线分析术后血清MMP-2、SCCA1表达水平对SNIP患者术后复发的预测价值。结果术后,2组血清MMP-2、SCCA1表达水平均较术前降低(P<0.05),但复发组血清MMP-2、SCCA1表达水平均高于未复发组(P<0.05)。Logistic回归分析显示,有吸烟史、术后未应用5-FU、Krouse分期为T3~T4期、术后血清MMP-2表达水平、SCCA1表达水平是影响SNIP患者术后复发的危险因素(P<0.05)。ROC曲线分析显示,术后血清MMP-2、SCCA1表达水平单独及二者联合预测SNIP患者术后复发的曲线下面积(AUC)分别为0.786、0.800、0.836,敏感度分别为83.33%、75.00%、91.67%,特异度分别为71.70%、79.25%、75.47%。结论术后血清MMP-2、SCCA1表达水平可作为预测SNIP患者术后复发的辅助指标,且二者联合预测的效果更佳。

CYFRA21-1、CA199、SCC、CRP联合检测在肺癌诊断中的应用价值

目的分析诊断肺癌中糖类抗原199(CA199)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、C反应蛋白(CRP)、鳞状细胞癌抗原(SCC)联合检测的价值。方法选取30例肺癌患者作为肺癌组,并纳入50例健康体检者作为健康组。两组均进行CYFRA21-1、SCC、CRP、CA199检查。对比两组CA199、CYFRA21-1、SCC、CRP水平;对比CA199、CYFRA21-1、SCC、CRP单独检测与联合检测对肺癌的诊断效能。结果肺癌组CA199(9.31±0.19)U/ml、CRP(23.49±1.36)mg/L、CYFRA21-1(4.43±0.09)ng/ml、SCC(29.50±0.16)ng/ml明显高于健康组的(3.27±0.11)U/ml、(5.48±1.15)mg/L、(1.20±0.16)ng/ml、(0.56±0.04)ng/ml,差异具有统计学意义(P<0.05)。CA199单独检测的诊断准确度、灵敏度和特异度分别为67.50%、46.67%、80.00%,CRP分别为73.75%、60.00%、82.00%,SCC分别为63.75%、40.00%、78.00%,CYFRA21-1分别为76.25%、66.67%、82.00%,联合检测分别为87.50%、90.00%、86.00%;CA199、CYFRA21-1、SCC、CRP联合检测的诊断准确度、特异度和灵敏度均高于单独检测。结论CA199、CYFRA21-1、SCC、CRP对肺癌诊断具有重要参考价值,通过联合检测能提高诊断特异度、准确度、敏感度。

肺癌患者放疗前后血清ProGRP、SCC和铁蛋白水平变化及其临床意义

目的 探讨肺癌患者放疗前后血清胃泌素释放肽前体(ProGRP)、鳞状细胞癌抗原(SCC)和铁蛋白(SF)水平变化及其临床意义。方法 选取122例非小细胞肺癌(NSCLC)患者作为研究组,根据放疗敏感性分为敏感组(n=43)及不敏感组(n=79)。另选取同期70例健康体检者作为对照组,检测并比较所有受试者血清ProGRP、SCC及SF水平,分析血清ProGRP、SCC及SF水平对NSCLC的诊断价值,并比较NSCLC患者放疗前后血清ProGRP、SCC及SF水平,分析不同放疗敏感性NSCLC患者放疗前后血清ProGRP、SCC及SF水平变化。结果 研究组血清ProGRP、SCC及SF水平均高于对照组(P<0.05);由ROC曲线可知,血清ProGRP、SCC及SF水平联合诊断NSCLC的AUC为0.926,高于三者单独诊断的0.784、0.822、0.805(P<0.05);NSCLC患者放疗后血清ProGRP、SCC及SF水平均低于放疗前(P<0.05);敏感度组放疗后血清ProGRP、SCC及SF水平低于放疗前及不敏感组(P<0.05)。结论 NSCLC患者血清ProGRP、SCC及SF水平升高,三者联合检测对NSCLC具有较高的诊断价值,监测三者水平变化有利于评估NSCLC患者放疗敏感性。

血清SCC-Ag、HE4、SMAD4水平与宫颈癌放化疗敏感性的相关性分析

目的分析血清鳞状细胞癌相关抗原(SCC-Ag)、人附睾分泌蛋白4(HE4)、SMAD4水平与宫颈癌放化疗敏感性的相关性。方法选取接受放化疗治疗的宫颈癌患者74例为研究对象,根据放化疗敏感性分为抵抗组和敏感组,分别有48例和26例。检测患者治疗前后血清SCC-Ag、HE4及SMAD4 mRNA水平,分析治疗前血清SCC-Ag、HE4、SMAD4水平与超声参数的相关性。绘制受试者工作特征曲线(ROC)描述治疗前SCC-Ag、HE4及SMAD4 mRNA水平对放化疗敏感性的预测价值。结果治疗后2组患者血清SCC-Ag、HE4水平较治疗前降低,SMAD4 mRNA水平较治疗前升高(P<0.05);且敏感组患者治疗前、后SCC-Ag、HE4水平均低于抵抗组,SMAD4 mRNA水平均高于抵抗组(P<0.05)。治疗前血清SCC-Ag、HE4与VI呈正相关(γ=0.518、0.544,P<0.05),SMAD4 mRNA与VI呈负相关(γ=-0.581,P<0.05)。ROC曲线显示,治疗前SCC-Ag、HE4及SMAD4 mRNA联合对放化疗敏感性的预测价值较高,AUC为0.863(95%CI:0.764~0.962)。结论血清SCC-Ag、HE4及SMAD4 mRNA水平与宫颈癌放化疗敏感性密切相关,且三者联合对放化疗敏感性具有较高的预测价值。

急性支气管炎患儿血清骨膜蛋白、SCCA表达及临床意义分析

目的检测急性支气管炎患儿血清骨膜蛋白、鳞状上皮细胞癌抗原(SCCA)水平,并探讨二者表达的临床意义。方法回顾性选取2018年10月至2020年4月于山东第二医科大学附属医院住院并接受治疗的78例急性支气管炎患儿为研究对象,纳入支气管炎组,根据疾病严重程度分为轻度52例和重度26例。选取同期健康体检的儿童86名作为对照组。检测并比较支气管炎组与对照组的骨膜蛋白、SCCA水平。比较轻度和重度急性支气管炎患儿的炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]、肺功能指标[第1秒用力呼气量(FEV1)、FEV1/用力肺活量(FVC)、最大呼气中段流量(MMEF)、最大呼气峰流速(PEF)]水平。采用Pearson法分析重度急性支气管炎患儿血清骨膜蛋白、SCCA水平与炎症因子水平、肺功能指标的相关性;以多因素Logistic回归分析对影响急性支气管炎加重的因素进行分析。结果支气管炎组患儿的血清骨膜蛋白、SCCA水平分别为(409.37±98.24)ng/L、(1.42±0.43)ng/mL,均明显高于对照组[(264.31±82.54)ng/L、(0.95±0.31)ng/mL],差异均有统计学意义(P<0.05)。重度急性支气管炎患儿的血清骨膜蛋白、SCCA、IL-6、TNF-α、hs-CRP水平分别为(524.46±123.94)ng/L、(1.82±0.52)ng/mL、(16.62±4.18)ng/L、(17.62±5.21)ng/L、(18.46±6.02)mg/L,均明显高于轻度急性支气管炎患儿[(348.92±64.28)ng/L、(1.22±0.24)ng/mL、(4.62±1.38)ng/L、(3.83±1.09)ng/L、(9.34±0.71)mg/L],FEV1、FEV1/FVC、MMEF、PEF水平分别为(2.06±0.27)V/L、56.62±6.26、(1.47±0.36)L/s、(4.33±0.62)L/s,均明显低于轻度急性支气管炎患儿[(3.12±0.46)V/L、67.38±6.14、(2.36±0.43)L/s、(5.64±0.71)L/s],差异均有统计学意义(P<0.05)。重度急性支气管炎患儿血清骨膜蛋白、SCCA水平与炎症因子均呈正相关(P<0.05),与肺功能指标均呈负相关(P<0.05)。骨膜蛋白、SCCA是影响急性支气管炎加重的独立危险因素(P<0.05)。结论急性支气管炎患儿血清骨膜蛋白、SCCA水平均显著升高,且随病情加重,血清骨膜蛋白、SCCA水平进一步升高,在急性支气管炎的病情评估中可能有重要作用。

非小细胞肺癌患者SCC、ProGRP及CEA水平变化及临床意义

目的探讨非小细胞肺癌(NSCLC)患者鳞状细胞癌相关抗原(SCC)、胃泌素释放肽前体(ProGRP)及癌胚抗原(CEA)水平变化及临床意义。方法回顾性分析2020年5月至2023年2月于首都医科大学附属北京友谊医院展开治疗的132例NSCLC患者的临床资料,设为A组;另抽取同期于本院治疗的71例肺良性病变患者,设为B组。比较两组患者SCC、ProGRP及CEA水平,分析不同临床特征NSCLC患者SCC、ProGRP及CEA水平,运用受试者工作特征(ROC)曲线分析SCC、ProGRP及CEA对NSCLC的诊断价值。结果A组患者血清SCC、ProGRP及CEA水平均高于B组患者,差异有统计学意义(P<0.05)。血清SCC、ProGRP、CEA及三者联合诊断NSC的AUC分别为0.691、0.815、0.822、0.832。不同病理类型、分化程度、临床分期及淋巴结转移的NSCLC患者血清SCC、ProGRP及CEA水平比较差异有统计学意义(P<0.05)。结论不同病理类型、分化程度、临床分期及淋巴结转移的NSCLC患者血清SCC、ProGRP及CEA存在差异,血清SCC、ProGRP及CEA均可有效辅助诊断NSCLC,且三者联合诊断能提高诊断效能。

血清HE4、SCC-Ag联合TCT检查诊断宫颈癌价值

目的:探讨血清人附睾上皮分泌蛋白4(HE4)、鳞状细胞癌相关抗原(SCC-Ag)联合宫颈薄层液基细胞学检测(TCT)诊断宫颈癌(CC)价值。方法:收集2021年10月-2023年7月本院病理确诊CC患者40例(CC组)、宫颈良性病变(CBL组,包括宫颈炎、宫颈上皮内瘤变)患者228例为CBL组。对比两组血清HE4、SCC-Ag水平,两组HE4、SCC-Ag、TCT检测CL阳性检出率;根据病理结果分析血清HE4、SCC-Ag水平、TCT诊断CL价值。结果:CC组血清HE4(188.71±39.15 pmol/L)、SCC-Ag(1.81±0.21 ng/ml)水平高于CBL组(73.65±11.52 pmol/L、0.64±0.12 ng/ml)(P<0.05)。TCT、HE4、SCC-Ag诊断CC的灵敏度(82.5%、72.5%、75.0%),特异度(77.6%、87.7%、86.8%),准确度(78.4%、85.5%、85.1%),3项指标联合诊断CC的灵敏度70.0%、特异度93.9%、准确度90.3%,联合检测准确度高于各单独指标检测(P<0.05)。结论:CC患者血清HE4、SCC-Ag水平及TCT检测阳性率均高于CBL患者,3项指标联合诊断准确度提高。

Ca125、CEA、TSGF和SCC检验在宫颈癌诊断中的价值研究

目的分析血清糖类抗原(Carbohydrate Antigen 125,Ca125)、癌胚抗原(Carcinoembryonic Antigen,CEA)、特异生长因子(Tumor Specific Growth Factor,TSGF)和鳞状细胞癌抗原(Squamous Cell Carcinoma Antigen,SCC)检验在宫颈癌诊断中的价值。方法回顾性分析2022年3月—2023年2月牟平区中医医院收治的68例宫颈癌患者资料,将其作为研究组;回顾性分析同期收治的66例宫颈良性疾病患者资料,将其作为对照组。两组患者均接受Ca125、CEA、TSGF和SCC检验。比较Ca125、CEA、TSGF、SCC联合检验与单独检验对于宫颈癌的诊断效能。结果研究组Ca125(49.65±10.23)U/mL、CEA(13.98±4.02)μg/L、TSGF(86.65±12.02)U/mL、SCC(11.89±2.56)μg/L的检验水平均高于对照组(15.65±11.02)U/mL、(3.28±0.98)μg/L、(52.02±10.23)U/mL、(2.02±1.89)μg/L,差异有统计学意义(t=18.517、21.024、17.935、20.783,P均<0.05)。联合检验对宫颈癌的诊断灵敏度、特异度、准确度高于单独Ca125、CEA、TSGF、SCC检验,差异有统计学意义(P均<0.05)。结论宫颈癌患者血清Ca125、CEA、TSGF、SCC表达水平明显升高,且联合检验进一步提高了诊断效能。

紫杉醇脂质体联合顺铂化疗对中晚期宫颈癌患者疗效及对FGFR4、SCCA水平的影响研究

目的探讨紫杉醇脂质体联合顺铂化疗对中晚期宫颈癌患者疗效及对FGFR4、SCCA水平的影响。方法选取2020年5月至2021年10月我院收治的中晚期宫颈癌患者93例,根据不同治疗方案分为观察组(n=48)和对照组(n=45),对照组采用顺铂化疗,观察组采用紫杉醇脂质体联合顺铂化疗。从入院当日开始,21天为1个疗程,治疗2个疗程。比较入院当日及治疗后治疗有效率、血清成纤维细胞生长因子受体(FGFR4)、鳞状细胞癌抗原(SCCA)、血管内皮生长因子(VEGF)水平及不良反应发生率。结果观察组血清FGFR4、SCCA、VEGF水平、不良反应发生率均显著低于对照组,治疗有效率高于对照组,差异有统计学意义(P值均<0.05)。结论紫杉醇脂质体联合顺铂化疗能够有效破坏肿瘤细胞遗传物质及新生血管,抑制肿瘤细胞增殖分化,并诱导其凋亡,从而延缓肿瘤发展进程,提升治疗有效率。

外周血SCC、ProGRP、CA-125及CYFRA21-1在非小细胞肺癌诊断和预后评估中的临床价值

目的探讨外周血鳞状上皮细胞癌抗原(SCC)、前胃泌素释放肽(ProGRP)、糖类癌抗原125(CA125)和细胞角蛋白19片段(CYFRA21-1)在非小细胞肺癌(NSCLC)诊断和预后评估中的临床价值。方法选取NSCLC患者(90例)作为肺癌组,另选取同期肺部良性病变作为良性组(82例)和体检健康者作为对照组(90例),统计3组外周血SCC、ProGRP、CA-125和CYFRA21-1水平,并采用ROC曲线分析SCC、ProGRP、CA-125和CYFRA21-1对NSCLC预后的预测效能,并采用Logistic回归分析NSCLC预后的影响因素。结果肺癌组血清SCC、ProGRP、CA-125和CYFRA21-1表达高于良性组和对照组(P<0.05);生存组血清SCC、ProGRP、CA-125和CYFRA21-1表达低于死亡组(P<0.05)。ROC曲线分析显示,SCC、ProGRP、CA-125、CYFRA21-1联合预测NSCLC预后的AUC为0.933,高于单一指标(P<0.05);采用二元Logistic回归分析,鳞癌、TNM分期T3~T4、淋巴结转移、SCC>1.57 ng/mL、ProGR P>73.04 pg/mL、CA125>29.53 U/mL、CYFRA21-1>3.00 ng/mL均为NSCLC预后的危险因素(P<0.05)。结论NSCLC患者外周血SCC、ProGRP、CA-125、CYFRA21-1表达升高,可用于患者预后评估。

血清CA125、CEA、SCC诊断宫颈癌的价值研究

目的探讨血清糖类抗原125(CA125)、癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCC)诊断宫颈癌的价值。方法选择宫颈癌患者62例为研究组,并选择同期健康人员62名为对照组,分别进行血清CA125、CEA、SCC检测。比较两组人员各指标水平,并分析联合检测的诊断效能。结果研究组CA125、CEA、SCC水平分别为(46.87±4.38)kU/L、(10.84±1.06)μg/L、(4.34±1.03)μg/L,均高于对照组的(12.84±1.48)kU/L、(1.37±0.22)μg/L、(0.61±0.12)μg/L(P<0.05)。各指标联合检测诊断准确性、敏感性均高于CA125、CEA、SCC单独检测(P<0.05)。结论宫颈癌患者血清CA125、CEA、SCC水平均有显著升高,对这三项指标进行联合检测有助于宫颈癌诊断效能的提高。